Psilocybin and Parkinson's: How Magic Mushrooms Improved Mood, Cognition and Movement

Published April 2026 · Psilocybin Science & News

New psilocybin Parkinson research from UCSF reveals that a single compound from magic mushrooms can safely improve mood, sharpen cognition and even reduce motor symptoms. This pilot study is the first of its kind — and the results are remarkable.

The Problem: Parkinson's Is More Than Tremors

Most people think of Parkinson's as a movement disorder. Shaking hands. Stiff muscles. Slow walking. And yes, those symptoms are real and difficult. But here is something many people do not know: up to 40% of Parkinson's patients also struggle with depression and anxiety. These mood problems are not just a side effect of feeling unwell. They are caused by the same brain changes that affect movement.

The worst part? Standard antidepressants often do not work well for Parkinson's patients. Many medications even clash with their existing Parkinson's drugs. So millions of people are stuck — their bodies slowly declining, their spirits sinking, and very few treatment options in sight.

How UCSF Designed the Psilocybin Parkinson Study

Dr. Joshua Woolley and Dr. Ellen Bradley at UCSF's Translational Psychedelic Research Program asked a bold question: could psilocybin safely treat mood dysfunction in people with Parkinson's? Until this study, no one had tried. Patients with neurodegenerative diseases were always excluded from psychedelic research — the assumption was that it would be too risky.

The team enrolled 12 patients with mild to moderate Parkinson's disease and a diagnosed depressive or anxiety disorder. The average age was 63. Five were women, seven were men. Every participant kept taking their regular Parkinson's medication throughout the study.

The psilocybin Parkinson treatment plan

Each patient received two psilocybin sessions, combined with psychological support before, during and after:

All twelve patients completed both sessions. No one dropped out. No one needed medical intervention. That alone was a breakthrough — it proved that psilocybin Parkinson therapy is feasible and tolerable.

Psilocybin Parkinson Results: Mood, Mind and Movement

The primary goal was simple: prove that it is safe. Mission accomplished. But the secondary findings are what made headlines around the world.

Depression and anxiety dropped significantly

Using two validated clinical scales — the Montgomery–Åsberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A) — the researchers measured a clear drop in both depression and anxiety scores. Depression scores fell by an average of 9.3 points. Anxiety scores fell by 3.8 points. These improvements were still visible at the three-month follow-up — long after psilocybin had left the body.

Motor symptoms improved too

This was the real surprise. Nobody expected a psychedelic compound to affect physical movement. But the MDS-UPDRS scale — the gold standard for measuring Parkinson's severity — showed clear gains across all sections:

The motor improvements lasted at least one month after the last dose. That means something changed in the brain that goes beyond the immediate psychedelic experience. These psilocybin Parkinson findings challenge what we thought was possible with a single compound.

Cognition got better as well

On three cognitive tests — Paired Associates Learning, Spatial Working Memory and Probabilistic Reversal Learning — patients scored significantly higher after treatment. Memory and learning ability are exactly the functions that Parkinson's gradually takes away. The fact that psilocybin moved those numbers in the right direction is remarkable.

Why Would Psilocybin Help Parkinson's Patients?

Two explanations stand out. First, psilocybin acts on serotonin receptors — the same system that regulates mood and cognition in Parkinson's patients. When mood improves, people move more, socialise more and exercise more. That alone can reduce motor symptoms.

Second — and this is the exciting part — psilocybin appears to trigger neuroplasticity. It helps the brain grow new connections and repair old ones. In Parkinson's, the brain is slowly losing those connections. The psilocybin Parkinson research suggests the compound may work against that process at a biological level. The fact that improvements lasted weeks after the substance left the body supports this idea.

"These results raise the exciting possibility that psilocybin may help the brain repair itself."

— Dr. Joshua Woolley, senior author and director of the TrPR Program at UCSF

A Psilocybin Parkinson Patient Story: "It Gave Me My Life Back"

Jeff Deming lives on a quiet piece of land in New Mexico. Six months before joining the trial, he could barely do the things he loved. Woodworking, tinkering, being outside — all of it had become a daily struggle. After the psilocybin sessions at UCSF, something shifted.

"Mentally, it's night and day," he told reporters. "Physically, I feel better than I did two or three years ago. It's a cliché, but it truly gave me my life back." For someone living with the double burden of Parkinson's and depression, psilocybin Parkinson therapy offered something no other treatment had.

Jeff's story is not unique. Several participants described a renewed sense of purpose, less fear about the future and a deeper emotional connection with their families. For people living with a progressive disease that has no cure, that kind of change is not small. It is everything.

Psilocybin Parkinson Safety: What About Side Effects?

Honesty matters — especially when it comes to safety. Ten out of twelve participants experienced mild to moderate side effects during the sessions. The most common ones were:

None of these required medical intervention. No one experienced psychosis, lasting hallucinations or a worsening of their Parkinson's symptoms. For a population that had always been excluded from psychedelic research out of caution, the psilocybin Parkinson safety profile is genuinely encouraging.

That said, psilocybin is not without risk for everyone. If you are curious about safety in general, our article Are Magic Mushrooms Dangerous? breaks it all down.

The Next Psilocybin Parkinson Trial: 100 Patients

Based on these promising results, a larger phase-2 study is already underway. It is funded by the Michael J. Fox Foundation — the world's most recognised Parkinson's research organisation, founded by the actor who has lived with the disease since 1991.

The new trial (NCT06455293) aims to enrol 100 participants across two sites: UCSF and Yale School of Medicine. Beyond the standard clinical measures, the team will use PET scans, MRI and transcranial magnetic stimulation (TMS) to map exactly how psilocybin changes the Parkinson's brain. Participants must be between 40 and 80 years old and have both Parkinson's and depressive symptoms.

This study is part of a broader wave of psilocybin therapy research that now spans depression, PTSD, OCD, addiction and — for the first time — neurodegenerative disease.

Psilocybin Parkinson Research: Why This Matters

Parkinson's disease affects more than 10 million people worldwide. Medications like levodopa manage symptoms, but nothing currently approved slows or reverses the disease. The mood and cognitive problems that come with it are largely undertreated.

This small study of twelve people will not change that overnight. But it opened a door that was previously locked. It proved that psilocybin Parkinson research is possible, safe and worth pursuing at scale. If the larger trial confirms what the pilot found, we could be looking at the first treatment that addresses mood, cognition and movement in Parkinson's patients — all from a single compound found in magic mushrooms.

Psilocybin is already approved for therapeutic use in Australia, and clinical programmes are running in Switzerland and the Czech Republic. The conversation is shifting from "Is this safe?" to "Who else can this help?" Parkinson's patients may be next in line.

Sources